Compare ETO & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ETO | DRTS |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | Israel |
| Employees | N/A | 125 |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 471.2M | 546.5M |
| IPO Year | 2004 | N/A |
| Metric | ETO | DRTS |
|---|---|---|
| Price | $26.70 | $7.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | 38.5K | ★ 225.1K |
| Earning Date | 01-01-0001 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $965.57 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.05 | $2.30 |
| 52 Week High | $31.11 | $8.60 |
| Indicator | ETO | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 36.52 | 49.41 |
| Support Level | $26.19 | $6.90 |
| Resistance Level | $27.67 | $7.75 |
| Average True Range (ATR) | 0.59 | 0.43 |
| MACD | -0.11 | -0.04 |
| Stochastic Oscillator | 33.94 | 50.34 |
Eaton Vance Tax-advtgd Global Divid Oppo is a diversified, closed-end management investment company. Its investment objective is to provide a high level of after-tax total return consisting of tax-advantaged dividend income and capital appreciation. The fund pursues its objective by investing in dividend-paying common and preferred stocks. The portfolio of investments consists of capital markets, chemicals, diversified, beverages, banks, electric utilities, oil, gas and consumable fuels, personal products, and other areas.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.